{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T22:19:14Z","timestamp":1649024354152},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.21024","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T22:10:09Z","timestamp":1635199809000},"page":"46-51","source":"Crossref","is-referenced-by-count":0,"title":["Glucocorticoid-induced redistribution lymphocytosis in mantle cell lymphoma with hyaline vascular Castleman disease-like features"],"prefix":"10.3960","volume":"62","author":[{"given":"Kazuto","family":"Togitani","sequence":"first","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuko","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Asagiri","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kochi Medical School Hospital, Nankoku, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiya","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Maddocks K. Update on mantle cell lymphoma. Blood. 2018; 132: 1647-1656.","DOI":"10.1182\/blood-2018-03-791392"},{"key":"2","unstructured":"2 Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, IARC Press. 2016."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tiemann M, Schrader C, Klapper W <i>et al.<\/i> Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005; 131: 29-38.","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Swerdlow SH, Campo E, Pileri SA <i>et al.<\/i> The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Yuan J, Li S, Liu X <i>et al.<\/i> Mantle cell lymphoma with mantle zone growth pattern. Am J Clin Pathol. 2019; 152: 132-145.","DOI":"10.1093\/ajcp\/aqz043"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Fajgenbaum DC, Uldrick TS, Bagg A <i>et al.<\/i> International, evidence-based consensus diagnostic criteria for HHV-8\u2013negative\/idiopathic multicentric Castleman disease. Blood. 2017; 129: 1646-1657.","DOI":"10.1182\/blood-2016-10-746933"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020; 135: 1353-1364.","DOI":"10.1182\/blood.2019000931"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013; 121: 1501-1509.","DOI":"10.1182\/blood-2012-08-452607"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 van Dongen JJM, Langerak AW, Br\u00fcggemann M <i>et al.<\/i> Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17: 2257-2317.","DOI":"10.1038\/sj.leu.2403202"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Robak T, Jin J, Pylypenko H <i>et al.<\/i> Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018; 19: 1449-1458.","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Oksenhendler E, Boutboul D, Fajgenbaum D <i>et al.<\/i> The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018; 180: 206-216.","DOI":"10.1111\/bjh.15019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Igawa T, Omote R, Sato H <i>et al.<\/i> A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features. Pathol Res Pract. 2017; 213: 1378-1383.","DOI":"10.1016\/j.prp.2017.09.015"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Yatabe Y, Suzuki R, Matsuno Y <i>et al.<\/i> Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int. 2001; 51: 747-761.","DOI":"10.1046\/j.1440-1827.2001.01277.x"},{"key":"14","unstructured":"14 Dobrea C, Mihai M, D\u0103n\u0103il\u0103 E <i>et al.<\/i> \u201cIn situ\u201d mantle cell lymphoma associated with hyaline-vascular Castleman disease. Rom J Morphol Embryol. 2011; 52: 1147-1151."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Siddiqi IN, Brynes RK, Wang E. B-cell lymphoma with hyaline vascular Castleman disease-like features: a clinicopathologic study. Am J Clin Pathol. 2011; 135: 901-914.","DOI":"10.1309\/AJCPF5AESY7OWIXF"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Wu W, Wang W, Franzen CA <i>et al.<\/i> Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. Blood Adv. 2021; 5: 185-197.","DOI":"10.1182\/bloodadvances.2020001665"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Rudelius M, Rosenfeldt MT, Leich E <i>et al.<\/i> Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. Haematologica. 2018; 103: 116-125.","DOI":"10.3324\/haematol.2017.177162"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009; 113: 4604-4613.","DOI":"10.1182\/blood-2008-10-185827"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004; 125: 697-706.","DOI":"10.1016\/j.mad.2004.06.010"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Bouazzaoui A, Spacenko E, Mueller G <i>et al.<\/i> Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract. Exp Hematol. 2011; 39: 238-249.","DOI":"10.1016\/j.exphem.2010.11.006"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018; 132: 2323-2330.","DOI":"10.1182\/blood-2018-05-848671"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/1\/62_21024\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T04:23:38Z","timestamp":1647059018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/1\/62_21024\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.21024","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"21024"}}